Coherus Oncology Statistics
Total Valuation
CHRS has a market cap or net worth of $114.48 million. The enterprise value is -$80.50 million.
Important Dates
The last earnings date was Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CHRS has 116.23 million shares outstanding. The number of shares has increased by 6.04% in one year.
| Current Share Class | 116.23M |
| Shares Outstanding | 116.23M |
| Shares Change (YoY) | +6.04% |
| Shares Change (QoQ) | +0.19% |
| Owned by Insiders (%) | 4.32% |
| Owned by Institutions (%) | 52.12% |
| Float | 111.19M |
Valuation Ratios
The trailing PE ratio is 0.63.
| PE Ratio | 0.63 |
| Forward PE | n/a |
| PS Ratio | 0.42 |
| Forward PS | 2.46 |
| PB Ratio | 0.97 |
| P/TBV Ratio | 1.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.44, with a Debt / Equity ratio of 0.34.
| Current Ratio | 1.44 |
| Quick Ratio | 1.36 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.63 |
Financial Efficiency
Return on equity (ROE) is 331.11% and return on invested capital (ROIC) is -29.48%.
| Return on Equity (ROE) | 331.11% |
| Return on Assets (ROA) | -9.92% |
| Return on Invested Capital (ROIC) | -29.48% |
| Return on Capital Employed (ROCE) | -50.32% |
| Revenue Per Employee | $1.19M |
| Profits Per Employee | $788,382 |
| Employee Count | 228 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 3.61 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.58% in the last 52 weeks. The beta is 0.89, so CHRS's price volatility has been lower than the market average.
| Beta (5Y) | 0.89 |
| 52-Week Price Change | -31.58% |
| 50-Day Moving Average | 0.85 |
| 200-Day Moving Average | 1.03 |
| Relative Strength Index (RSI) | 59.11 |
| Average Volume (20 Days) | 1,400,153 |
Short Selling Information
The latest short interest is 32.34 million, so 27.82% of the outstanding shares have been sold short.
| Short Interest | 32.34M |
| Short Previous Month | 31.23M |
| Short % of Shares Out | 27.82% |
| Short % of Float | 29.08% |
| Short Ratio (days to cover) | 23.65 |
Income Statement
In the last 12 months, CHRS had revenue of $272.21 million and earned $179.75 million in profits. Earnings per share was $1.55.
| Revenue | 272.21M |
| Gross Profit | 151.86M |
| Operating Income | -88.48M |
| Pretax Income | -29.72M |
| Net Income | 179.75M |
| EBITDA | -83.83M |
| EBIT | -88.48M |
| Earnings Per Share (EPS) | $1.55 |
Full Income StatementBalance Sheet
The company has $237.64 million in cash and $41.03 million in debt, giving a net cash position of $196.61 million or $1.69 per share.
| Cash & Cash Equivalents | 237.64M |
| Total Debt | 41.03M |
| Net Cash | 196.61M |
| Net Cash Per Share | $1.69 |
| Equity (Book Value) | 119.83M |
| Book Value Per Share | 1.03 |
| Working Capital | 116.58M |
Full Balance SheetCash Flow
| Operating Cash Flow | -105.87M |
| Capital Expenditures | n/a |
| Free Cash Flow | -105.87M |
| FCF Per Share | -$0.91 |
Full Cash Flow StatementMargins
Gross margin is 55.79%, with operating and profit margins of -32.50% and 66.03%.
| Gross Margin | 55.79% |
| Operating Margin | -32.50% |
| Pretax Margin | 21.72% |
| Profit Margin | 66.03% |
| EBITDA Margin | -30.80% |
| EBIT Margin | -32.50% |
| FCF Margin | n/a |
Dividends & Yields
CHRS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.04% |
| Shareholder Yield | -6.04% |
| Earnings Yield | 154.81% |
| FCF Yield | -91.18% |
Analyst Forecast
The average price target for CHRS is $4.68, which is 375.13% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.68 |
| Price Target Difference | 375.13% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | -2.58% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CHRS has an Altman Z-Score of -3.65 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.65 |
| Piotroski F-Score | 5 |